Literatur

1. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017 Jan 19.

2. van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. Nature reviews Rheumatology. 2015 Feb; 11(2):110–118.

3. Sampaio-Barros PD, Bertolo MB, Kraemer MH, Marques-Neto JF, Samara AM. Undifferentiated spondyloarthropathies: a 2-year follow-up study. Clinical rheumatology. 2001; 20(3):201–206.

4. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Annals of the rheumatic diseases. 2011 Aug; 70(8):1369–1374.

5. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and rheumatism. 1984 Apr; 27(4):361–368.

6. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of Spondy¬loArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Annals of the rheumatic diseases. 2009 Jun; 68(6):770–776.

7. Wen C, Zheng Z, Shao T, Liu L, Xie Z, Le Chatelier E, et al. Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis. Genome biology. 2017 Jul 27; 18(1):142.

8. Costello ME, Ciccia F, Willner D, Warrington N, Robinson PC, Gardiner B, et al. Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. Arthritis & rheumatology. 2015 Mar; 67(3):686–691.

9. Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiocchia G, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Annals of the rheumatic diseases. 2017 Sep; 76(9):1614–1622.

10. Jacques P, Lambrecht S, Verheugen E, Pauwels E, Kollias G, Armaka M, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Annals of the rheumatic diseases. 2014 Feb; 73(2):437–445.

11. de Koning A, Schoones JW, van der Heijde D, van Gaalen FA. Pathophysiology of axial spondyloarthritis: Consensus and controversies. European journal of clinical investigation. 2018 Feb 20.

12. Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Current opinion in rheumatology. 2000 Jul; 12(4):239–247.

13. Masson Behar V, Dougados M, Etcheto A, Kreis S, Fabre S, Hudry C, et al. Diagnostic delay in axial spondyloarthritis: A cross-sectional study of 432 patients. Joint, bone, spine : revue du rhumatisme. 2017 Jul; 84(4):467–471.

14. Sorensen J, Hetland ML, all departments of rheumatology in D. Diagnostic delay in patients with rheumatoid arthritis, psori¬atic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Annals of the rheumatic diseases. 2015 Mar; 74(3):e12.

15. Feldtkeller E, Rudwaleit M. Comment on 'Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry'. Annals of the rheumatic diseases. 2014 Dec; 73(12):e77.

16. Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, et al. Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology. 2019 Mar 21.

17. Seo MR, Baek HL, Yoon HH, Ryu HJ, Choi HJ, Baek HJ, et al. Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis. Clinical rheumatology. 2015 Aug; 34(8):1397–1405.

18. Ortolan A, van Lunteren M, Ramiro S, Ramonda R, Landewe RBM, Dagfinrud H, et al. Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort. Arthritis research & therapy. 2018 Oct 1; 20(1):218.

19. Bakker PA, Ramiro S, Ez-Zaitouni Z, van Lunteren M, Berg IJ, Landewe R, et al. Is it useful to repeat MRI of the sacroiliac joints after three months or one year in the diagnostic process of patients with chronic back pain suspected of axial spondyloarthritis? Arthritis & rheumatology. 2018 Sep 11.

20. Poulain C, D'Agostino MA, Thibault S, Daures JP, Ferkal S, Le Corvoisier P, et al. Can power Doppler ultrasound of the entheses help in classifying recent axial spondyloarthritis? Data from the DESIR cohort. RMD open. 2018; 4(2):e000686.

21. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Annals of the rheumatic diseases. 2015 Jan; 74(1):65–73.

22. Haroon M, O'Rourke M, Ramasamy P, Murphy CC, FitzGerald O. A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). Annals of the rheumatic diseases. 2015 Nov; 74(11):1990–1995.

23. Sykes MP, Hamilton L, Jones C, Gaffney K. Prevalence of axial spondyloarthritis in patients with acute anterior uveitis: a cross-sectional study utilising MRI. RMD open. 2018; 4(1):e000553.

24. Oliveira TL, Maksymowych WP, Lambert RGW, Muccioli C, Fernandes ARC, Pinheiro MM. Sacroiliac Joint Magnetic Resonance Imaging in Asymptomatic Patients with Recurrent Acute Anterior Uveitis: A Proof-of-concept Study. The Journal of rheumatology. 2017 Dec; 44(12):1833–1840.

25. Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nature reviews Rheumatology. 2018 Jun; 14(6):363–371.

26. Yap KS, Ye JY, Li S, Gladman DD, Chandran V. Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis. Annals of the rheumatic diseases. 2018 Aug 4.

27. Bratu VA, Hausermann P, Walker UA, Daikeler T, Zubler V, Jaeger VK, et al. Do patients with skin psoriasis show subclinical axial inflammation on MRI of the sacroiliac joints and entire spine? Arthritis care & research. 2018 Sep 22.

28. Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, et al. Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. The Journal of rheumatology. 2018 Jul 1.

29. Karreman MC, Luime JJ, Hazes JMW, Weel A. The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Journal of Crohn's & colitis. 2017 May 1; 11(5):631–642.

30. Ossum AM, Palm O, Lunder AK, Cvancarova M, Banitalebi H, Negard A, et al. Ankylosing Spondylitis and Axial Spondyloar¬thritis in Patients With Long-term Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study. Journal of Crohn's & colitis. 2018 Jan 5; 12(1):96–104.

31. Luchetti MM, Ciccia F, Avellini C, Benfaremo D, Guggino G, Farinelli A, et al. Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease. The Journal of rheumatology. 2018 May; 45(5):630–637.

32. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec; 21(12):2286–2291.

33. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Jan; 68(1):18–24.

34. van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the rheumatic diseases. 2017 Jun; 76(6):978–991.

35. Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan; 77(1):3–17.

36. Dubreuil M, Peloquin C, Zhang Y, Choi HK, Inman RD, Neogi T. Validity of ankylosing spondylitis diagnoses in The Health Improvement Network. Pharmacoepidemiology and drug safety. 2016 Apr; 25(4):399–404.

37. Walsh JA, Pei S, Penmetsa GK, Leng J, Cannon GW, Clegg DO, et al. Cohort identification of axial spondyloarthritis in a large healthcare dataset: current and future methods. BMC musculoskeletal disorders. 2018 Sep 5; 19(1):317.

38. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treat¬ment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis & rheumatology. 2019 Oct; 71(10):1599–1613.

39. Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the rheumatic diseases. 2017 Jul 06.

40. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. The Cochrane database of systematic reviews. 2008 Jan 23(1):CD002822.

41. Millner JR, Barron JS, Beinke KM, Butterworth RH, Chasle BE, Dutton LJ, et al. Exercise for ankylosing spondylitis: An evidence-based consensus statement. Seminars in arthritis and rheumatism. 2016 Feb; 45(4):411–427.

42. Levitova A, Hulejova H, Spiritovic M, Pavelka K, Senolt L, Husakova M. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis research & therapy. 2016 Nov 25; 18(1):275.

43. Florez MT, Almodovar R, Garcia Perez F, Rodriguez Cambron AB, Carmona L, Perez Manzanero MA, et al. The EJES-3D tool for personalized prescription of exercise in axial spondyloarthritis through multimedia animations: pilot study. Rheumatology international. 2018 Jul; 38(7):1277–1284.

44. Paul L, Coulter EH, Cameron S, McDonald MT, Brandon M, Cook D, et al. Web-based physiotherapy for people with axial spondyloarthritis (WEBPASS) – a study protocol. BMC musculoskeletal disorders. 2016 Aug 24; 17(1):360.

45. Jacquemin C, Servy H, Molto A, Sellam J, Foltz V, Gandjbakhch F, et al. Physical Activity Assessment Using an Activity Tracker in Patients with Rheumatoid Arthritis and Axial Spondyloarthritis: Prospective Observational Study. JMIR mHealth and uHealth. 2018 Jan 2; 6(1):e1.

46. Gossec L, Guyard F, Leroy D, Lafargue T, Seiler M, Jacquemin C, et al. Detection of flares by decrease in physical activity, collected using wearable activity trackers, in rheumatoid arthritis or axial spondyloarthritis: an application of Machine-Learning analyses in rheumatology. Arthritis care & research. 2018 Sep 22.

47. Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/Spondylitis Associa¬tion of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylo¬sing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis care & research. 2016 Feb; 68(2):151–166.

48. Kroon FP, van der Burg LR, Ramiro S, Landewe RB, Buchbinder R, Falzon L, et al. Nonsteroidal Anti-inflammatory Einnahme Drugs for Axial Spondyloarthritis: A Cochrane Review. The Journal of rheumatology. 2016 Mar; 43(3):607–617.

49. Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Annals of the rheumatic diseases. 2016 Jun; 75(6):1152–1160.

50. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis and rheumatism. 2005 Jun; 52(6):1756–1765.

51. Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016 Aug; 75(8):1438–1443.

52. Proft F, Muche B, Listing J, Rios-Rodriguez V, Sieper J, Poddubnyy D. Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis fac¬tor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial. BMJ open. 2017 Jun 10; 7(6):e014591.

53. Coxib, traditional NTC, Bhala N, Emberson J, Merhi A, Abramson S, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31; 382(9894):769–779.

54. Nissen SE, Yeomans ND, Solomon DH, Luscher TF, Libby P, Husni ME, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine. 2016 Dec 29; 375(26):2519–2529.

55. Chan FKL, Ching JYL, Tse YK, Lam K, Wong GLH, Ng SC, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry¬independent, double-blind, double-dummy, randomised trial. Lancet. 2017 Jun 17; 389(10087):2375–2382.

56. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Annals of the rheumatic diseases. 2011 Nov; 70(11):1921–1925.

57. Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality: A Population-Based Study. Annals of internal medicine. 2015 Sep 15; 163(6):409–416.

58. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism. 2006 Jul; 54(7):2136–2146.

59. Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014 Jan; 73(1):39–47.

60. Davis JC, Jr., Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis and rheumatism. 2003 Nov; 48(11):3230–3236.

61. Inman RD, Davis JC, Jr., Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis and rheumatism. 2008 Nov; 58(11):3402–3412.

62. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 06; 359(9313):1187–1193.

63. Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nature reviews Rheumatology. 2016 May; 12(5):282–295.

64. Spadaro A, Lubrano E, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, et al. Remission in ankylosing spondylitis treated with anti-TNF-alpha drugs: a national multicentre study. Rheumatology. 2013 Oct; 52(10):1914–1919.

65. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Annals of the rheumatic diseases. 2013 Jun; 72(6):815–822.

66. Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis & rheumatology. 2014 Aug; 66(8):2091–2102.

67. Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, et al. A Randomized, Double-Blind, Placebo-Controlled, Sixteen-Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2015 Oct; 67(10):2702–2712.

68. Lubrano E, Perrotta FM, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, et al. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-alpha drugs: an Italian multicenter study. The Journal of rheumatology. 2015 Feb; 42(2):258–263.

69. Lorenzin M, Ortolan A, Frallonardo P, Oliviero F, Punzi L, Ramonda R. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC musculoskeletal disorders. 2015 Jul 24; 16:166.

70. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004 Jun; 63(6):665–670.

71. van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis and rheumatism. 2008 Oct; 58(10):3063–3070.

72. van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis research & therapy. 2009; 11(4):R127.

73. van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis and rheumatism. 2008 May; 58(5):1324–1331.

74. Braun J, Baraliakos X, Hermann KG, Deodhar A, van der Heijde D, Inman R, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Annals of the rheumatic diseases. 2014 Jun; 73(6):1107–1113.

75. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibi¬tors on radiographic progression in ankylosing spondylitis. Arthritis and rheumatism. 2013 Oct; 65(10):2645–2654.

76. Maas F, Arends S, Wink FR, Bos R, Bootsma H, Brouwer E, et al. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-alpha inhibitors. PloS one. 2017; 12(6):e0177231.

77. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford). 2007 Sep; 46(9):1450–1453.

78. Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, et al. TNF blockers inhibit spinal radiographic progres¬sion in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Annals of the rheumatic diseases. 2017 Sep 22.

79. Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2017 Mar; 76(3):571–592.

80. Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD open. 2019; 5(2):e001005.

81. Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Annals of the rheumatic diseases. 2017 Jun; 76(6):1070–1077.

82. Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2018 Oct 20.

83. Van der Heijde D, Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untrea¬ted with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, doub¬le-blind, active-controlled and placebo-controlled trial. Lancet. 2018.

84. Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Ostergaard M, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2019 Dec 5.

85. Erdes S, Nasonov E, Kunder E, Pristrom A, Soroka N, Shesternya P, et al. Primary efficacy of netakimab, a novel inter¬leukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clinical and experimental rheumatology. 2019 Apr 16.

86. Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Annals of the rheumatic diseases. 2007 Mar; 66(3):419–421.

87. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Annals of the rheumatic diseases. 2005 Jan; 64(1):124–126.

88. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of sulfasalazine in patients with inflam¬matory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Annals of the rheumatic diseases. 2006 Sep; 65(9):1147–1153.

89. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011 Jun; 70(6):1108–1110.

90. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis fac¬tor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis and rheumatism. 2010 May; 62(5):1290–1297.

91. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Annals of the rheumatic diseases. 2005 Feb; 64(2):296–298.

92. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizu¬mab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Annals of the rheumatic diseases. 2014 Jan; 73(1):95–100.

93. Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Annals of the rheumatic diseases. 2015 Jun; 74(6):1051–1057.

94. Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M, et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. Journal of the American Academy of Dermatology. 2017 Oct 03.

95. van der Heijde D, Gensler L, Deodhar A, Baraliakos X, Poddubnyy D, Farmer MK, et al. Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study. Annals of the rheumatic diseases. 2018; Volume 77(Suppl):A70.

96. Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three Multicenter, Randomized, Double-Blind, Pla¬cebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis & rheumatology. 2018 Sep 18.

97. Baeten D, Ostergaard M, Wei JC, Sieper J, Jarvinen P, Tam LS, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spon¬dylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Annals of the rheumatic diseases. 2018 Sep; 77(9):1295–1302.

98. van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Annals of the rheumatic diseases. 2017 Aug; 76(8):1340–1347.

99. Maksymowych WP, Heijde DV, Baraliakos X, Deodhar A, Sherlock SP, Li D, et al. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology. 2018 Aug 1; 57(8):1390–1399.

100. van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, pla¬cebo-controlled, phase 2/3 trial. Lancet. 2019 Dec 7; 394(10214):2108–2117.

101. van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a ran¬domised, placebo-controlled, phase 2 trial. Lancet. 2018 Dec 1; 392(10162):2378–2387.

102. Pathan E, Abraham S, Van Rossen E, Withrington R, Keat A, Charles PJ, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Annals of the rheumatic diseases. 2013 Sep 01; 72(9):1475–1480.

103. Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis research & therapy. 2016 Jan 20; 18:25.

104. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Annals of the rheumatic diseases. 2013 Oct; 72(10):1605–1612.

105. Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, et al. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-alpha agents in rheumatic diseases; A systematic review and meta-analysis. Journal of autoim¬munity. 2017 May; 79:4–16.

106. Avouac J, Molto A, Abitbol V, Etcheto A, Salcion A, Gutermann L, et al. Systematic switch from innovator infliximab to bio¬similar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Seminars in arthritis and rheumatism. 2018 Apr; 47(5):741–748.

107. Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Annals of the rheumatic diseases. 2017 Aug; 76(8):1426–1431.